Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INHL004 (budesonide)
- Development stage
- Approved
- Lead developer
- Lee's Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Inhalation
01
Overview
INHL004 is an inhaled suspension formulation of budesonide, a potent synthetic glucocorticoid corticosteroid, developed by Lee's Pharmaceutical through its subsidiary Zhaoke Pharmaceutical (Guangzhou) (ZKGZ Biotech). Budesonide is a well-established anti-inflammatory agent used for the maintenance treatment of chronic respiratory diseases. It functions as an agonist of the glucocorticoid receptor (NR3C1); upon binding, the receptor-ligand complex translocates to the nucleus where it modulates gene transcription to inhibit the production of pro-inflammatory cytokines and mediators while upregulating anti-inflammatory proteins. This action effectively reduces airway inflammation, edema, and hyperreactivity. INHL004 is specifically designed for administration via a nebulizer and has received marketing approval in China for the treatment of bronchial asthma and chronic obstructive pulmonary disease (COPD).
- Other names
- budesonide suspension for inhalation
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on INHL004 (budesonide).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INHL004 (budesonide).